清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

New Approaches to Myelodysplastic Syndrome Treatment

医学 国际预后积分系统 骨髓增生异常综合症 来那度胺 癸他滨 贫血 内科学 肿瘤科 去铁斯若 促红细胞生成素 临床试验 重症监护医学 骨髓 地中海贫血 多发性骨髓瘤 基因表达 化学 DNA甲基化 生物化学 基因
作者
Alexandre Bazinet,Guillermo Montalban‐Bravo
出处
期刊:Current Treatment Options in Oncology [Springer Science+Business Media]
卷期号:23 (5): 668-687 被引量:27
标识
DOI:10.1007/s11864-022-00965-1
摘要

The treatment of myelodysplastic syndromes (MDS) begins with risk stratification using a validated tool such as the International Prognostic Scoring System (IPSS) or its revised version (IPSS-R). This divides patients into lower- and higher- risk categories. Although treatment objectives in lower-risk MDS (LR-MDS) have traditionally been directed at improving cytopenias (usually anemia) as well as quality of life, recent data supports a potential role for early intervention in delaying transfusion dependency. In addition, careful individualized risk stratification incorporating clinical, cytogenetic, and mutational data might help identify patients at higher-than-expected risk for progression. Given the need for supportive care with red blood cell (RBC) transfusions leading to iron overload, iron chelation should be considered for patients with heavy transfusion requirements at risk for end-organ complications. For patients with LR-MDS and isolated anemia, no high-risk features, and endogenous erythropoietin (EPO) levels below 500 U/L, erythropoiesis-stimulating agents (ESAs) can be attempted to improve anemia. Some LR-MDS patient subgroups may also benefit from specific therapies including luspatercept (MDS with ring sideroblasts), lenalidomide (MDS with deletion 5q), or immunosuppressive therapy (hypocellular MDS). LR-MDS patients failing the above options, or those with multiple cytopenias and/or higher-risk features, can be considered for oral low-dose hypomethylating agent (HMA) therapy. Alternatively, these patients may be enrolled on a clinical trial with promising agents targeting the transforming-growth factor beta (TGF-β) pathway, the hypoxia-inducible factor (HIF) pathway, telomerase activity, inflammatory signaling, or the splicing machinery. In higher-risk MDS (HR-MDS), therapy seeks to modify the natural history of the disease and prolong survival. Eligible patients should be considered for curative allogeneic hematopoietic stem cell transplantation (aHSCT). Despite promising novel combinations, the HMAs azacitidine (AZA) or decitabine (DAC) are still the standard of care for these patients, with intensive chemotherapy-based approaches being a potential option in a small subset of patients. Individuals who fail to respond or progress after HMA experience dismal outcomes and represent a major unmet clinical need. Such patients should be treated as part of a clinical trial if possible. Experimental agents to consider include venetoclax, myeloid cell leukemia 1 (MCL-1) inhibitors, eprenetapopt, CPX-351, immunotherapies (directed towards CD47, TIM3, or CD70), interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors, pevonedistat, seclidemstat, and eltanexor. In this review, we extensively discuss the current landscape of experimental therapies for both LR- and HR-MDS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小文同学发布了新的文献求助10
2秒前
打打的应助被有志者采纳,获得20
2秒前
竹捷发布了新的文献求助10
3秒前
11完成签到 ,获得积分10
4秒前
领导范儿的应助被11采纳,获得10
18秒前
wcl完成签到,获得积分10
23秒前
YZY完成签到 ,获得积分10
37秒前
flb1227完成签到 ,获得积分10
45秒前
蔡勇强完成签到 ,获得积分10
50秒前
RRui完成签到,获得积分10
56秒前
alei089完成签到 ,获得积分10
1分钟前
Benhnhk21完成签到,获得积分10
1分钟前
vbnn完成签到 ,获得积分10
1分钟前
1分钟前
俊逸蛋挞完成签到 ,获得积分10
1分钟前
奔跑的应助被姚老表采纳,获得30
1分钟前
有志者发布了新的文献求助20
1分钟前
眯眯眼的安雁完成签到 ,获得积分10
1分钟前
阿申爱乐的应助被Benhnhk21采纳,获得30
1分钟前
Agatha完成签到 ,获得积分10
1分钟前
cadcae完成签到,获得积分10
1分钟前
有志者完成签到,获得积分10
1分钟前
风中可仁完成签到 ,获得积分10
1分钟前
文若完成签到,获得积分10
1分钟前
奔跑的应助被qin采纳,获得10
2分钟前
2分钟前
leng发布了新的文献求助10
2分钟前
小白白完成签到 ,获得积分10
2分钟前
2分钟前
木子完成签到 ,获得积分10
2分钟前
阿申爱乐的应助被Benhnhk21采纳,获得30
2分钟前
虚拟的白云完成签到,获得积分10
2分钟前
qin发布了新的文献求助10
3分钟前
45度科研狗完成签到 ,获得积分10
3分钟前
Jack_20708124完成签到 ,获得积分10
3分钟前
阿申爱乐的应助被Benhnhk21采纳,获得30
3分钟前
ikutovaya完成签到,获得积分10
3分钟前
atra2107完成签到 ,获得积分10
3分钟前
zhangguo完成签到 ,获得积分10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195230
求助须知:如何正确求助?哪些是违规求助? 9580992
关于积分的说明 21873110
捐赠科研通 7795292
什么是DOI,文献DOI怎么找? 3437973
关于科研通互助平台的介绍 2561284
邀请新用户注册赠送积分活动 2484708